Gefitinib

Revision as of 13:01, 28 November 2010 by David Canner (Talk | contribs)

Marketed By: AstraZeneca & Teva
Major Indication: Pancreatic & Small Cel Lung Cancer
Drug Class: EGFR Inhibitor
Date of FDA Approval (Expiration): 2003 (2013)
2009 Sales: $268 Million
Why You Should Care: It is the first selective inhibitor of Epidermal Growth Factor Receptors approved by the FDA
The following is a list of Pharmacokinetic Parameters. See: Pharmaceutical Drugs for more information

Epidermal Growth Factor Receptor Inhibitor Pharmacokinetics Comparison at Equivalent Dosages ^[1]^[2]
Parameter	Erlotinib (Tarceva)	Gefitinib (Iressa)
T_max (hr)	2.0	5.4
C_max (ng/ml)	69.6	130
Bioavailability (%)	99	59
Protein Binding (%)	93	90
T_1/2 (hr)	9.4	26.9
AUC (ng/ml/hr)	20577	3850
IC₅₀ (nM)	2	23
Typical Dosage (mg)	150	250
Metabolism	Hepatic - (CYP3A4, CYP3A5, CYP2D6, CYP1A1)	Hepatic - (CYP3A4, CYP3A5, CYP2D6, CYP1A1, CYP1A2)

↑ Hamilton M, Wolf JL, Rusk J, Beard SE, Clark GM, Witt K, Cagnoni PJ. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2166-71. PMID:16609030 doi:10.1158/1078-0432.CCR-05-2235
↑ Bergman E, Forsell P, Persson EM, Knutson L, Dickinson P, Smith R, Swaisland H, Farmer MR, Cantarini MV, Lennernas H. Pharmacokinetics of gefitinib in humans: the influence of gastrointestinal factors. Int J Pharm. 2007 Aug 16;341(1-2):134-42. Epub 2007 Apr 6. PMID:17482782 doi:10.1016/j.ijpharm.2007.04.002

Proteopedia Page Contributors and Editors (what is this?)